MindBio Therapeutics Corp. (CSE:MBIO)
Canada flag Canada · Delayed Price · Currency is CAD
2.490
-0.210 (-7.78%)
At close: Dec 5, 2025

MindBio Therapeutics Income Statement

Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year
TTM FY 2025 FY 2024 FY 2023 FY 2022
Period Ending
Sep '25 Jun '25 Jun '24 Jun '23 Jun '22
Selling, General & Admin
1.031.060.631.822.9
Research & Development
----2.46
Amortization of Goodwill & Intangibles
----0.04
Operating Expenses
3.031.90.633.225.4
Operating Income
-3.03-1.9-0.63-3.22-5.4
Interest Expense
-0.51-0.58-0.35-0.45-0.18
Currency Exchange Gain (Loss)
-0.1--0.01-0.11
Other Non Operating Income (Expenses)
-0.03-0.030.58-0.25-1.78
EBT Excluding Unusual Items
-3.67-2.51-0.41-3.92-7.47
Gain (Loss) on Sale of Investments
---0.01-0.02-
Asset Writedown
-0.59-0.59---
Other Unusual Items
0.290.290.01-0.35-
Pretax Income
-3.97-2.81-0.41-4.29-7.47
Net Income
-3.97-2.81-0.41-4.29-7.47
Net Income to Common
-3.97-2.81-0.41-4.29-7.47
Shares Outstanding (Basic)
11000
Shares Outstanding (Diluted)
11000
Shares Change (YoY)
98.05%54.23%20.80%106.14%-
EPS (Basic)
-6.03-5.47-1.24-15.57-55.96
EPS (Diluted)
-6.03-5.47-1.24-15.57-55.96
EBITDA
--1.78---5.36
D&A For EBITDA
-0.12--0.04
EBIT
-3.03-1.9-0.63-3.22-5.4
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.